How to Get Praluent (Alirocumab) in South Dakota

What Is Praluent and Why Do South Dakota Patients Need It

Praluent (alirocumab) is a monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab keeps more LDL receptors active on the liver surface, which pulls more LDL-C out of the bloodstream. The FDA approved alirocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what statins alone can achieve [1].

South Dakota has approximately 885,000 residents. Familial hypercholesterolemia affects roughly 1 in 250 people in the general population, meaning an estimated 3,500 South Dakotans may carry a causative FH mutation [2]. Many go undiagnosed for years because primary care panels in rural states are large and lipid cascade-screening is inconsistent.

The key ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% versus placebo (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) in patients who had experienced an acute coronary syndrome within the prior year and remained on high-intensity statin therapy [3]. That trial was published in the New England Journal of Medicine in 2018 and remains the foundation of guideline recommendations for PCSK9 inhibitor use.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD and LDL-C 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable (Class IIa, Level A)" [4]. South Dakota providers follow these same national guidelines.

How to Get a Praluent Prescription in South Dakota

Getting a Praluent prescription in South Dakota takes four concrete steps: establish eligibility through lab work, see a licensed prescriber (in-person or via telehealth), complete prior authorization, and fill through a specialty pharmacy.

Step 1. Confirm your labs. Most payers and prescribers require a recent fasting lipid panel showing LDL-C at or above 70 mg/dL (for established ASCVD) or 100 mg/dL (for HeFH without prior cardiovascular event) despite at least one documented trial of high-intensity statin therapy. LabCorp and Sanford Health laboratory locations across South Dakota can run a standard fasting lipid panel within 24 hours [5].

Step 2. See a prescriber. Any South Dakota-licensed MD, DO, NP, or PA may prescribe alirocumab. Cardiologists and endocrinologists most commonly initiate the prescription, but primary care providers can do so as well. If no in-person appointment is available promptly, telehealth is fully permitted.

Step 3. Complete prior authorization. Your prescriber's office submits clinical documentation to your insurer. The PA packet typically requires your most recent lipid panel, a list of statins previously tried and doses used, the reason for statin discontinuation or failure, and the ICD-10 diagnosis code (E78.01 for pure HeFH or I25.10 for ASCVD).

Step 4. Fill at a specialty pharmacy. Once PA is approved, the prescription routes to a specialty pharmacy. Regeneron and Sanofi operate a patient services hub called MyPraluent that coordinates specialty pharmacy fulfillment and financial assistance [6].

Telehealth Options for Praluent in South Dakota

South Dakota law permits telehealth prescribing of alirocumab without a prior in-person visit, provided the prescriber conducts a synchronous audio-visual evaluation and reviews the patient's medical history and labs. This rule aligns with the South Dakota Board of Medical and Osteopathic Examiners telehealth practice standards [7].

Telehealth is genuinely useful here. Rural patients in places like Mobridge, Winner, or Faith can connect with a board-certified cardiologist or lipidologist via video without driving 150 to 200 miles to Sioux Falls or Rapid City. HealthRX connects South Dakota patients with licensed prescribers who specialize in lipid management and can initiate the Praluent PA process during the same visit.

A 2023 analysis published in JAMA Cardiology found that telehealth-initiated PCSK9 inhibitor prescriptions had PA approval rates within 5 percentage points of in-person-initiated prescriptions (68.2% vs. 71.4%), suggesting no meaningful disadvantage to the telehealth route [8].

The prescriber must be licensed in South Dakota regardless of their physical location. After the video visit, the prescriber sends the prescription electronically to the specialty pharmacy and submits PA documentation to your insurer. Patients do not need to be physically present at any point after the initial video consultation.

Labs Required Before Starting Praluent in South Dakota

A fasting lipid panel is the minimum requirement. Most prescribers and payers also request a complete metabolic panel to rule out secondary causes of hypercholesterolemia such as hypothyroidism or nephrotic syndrome [9]. Thyroid-stimulating hormone (TSH) is frequently added as well.

For HeFH diagnosis confirmation, some payers require genetic testing showing a pathogenic variant in LDLR, APOB, or PCSK9, or a Dutch Lipid Clinic Network score of 6 or above [10]. A score of 6 requires a combination of clinical history, physical findings (e.g., tendon xanthoma), family history, and LDL-C level; genetic testing is not always mandatory.

Alirocumab itself does not require hepatic monitoring, renal dose adjustment, or muscle enzyme testing, which distinguishes it from statins [1]. Follow-up labs typically include a repeat fasting lipid panel 4 to 8 weeks after starting therapy to confirm the LDL-C response, per the ACC/AHA guideline recommendation to reassess within 4 to 12 weeks of any lipid-lowering therapy change [4].

Sanford Health operates outpatient laboratory draw stations in Aberdeen, Brookings, Pierre, Rapid City, Sioux Falls, Watertown, and Yankton. Monument Health runs draw stations in the western Black Hills region [11]. Most commercial labs in South Dakota process lipid panels the same day or next day.

Prior Authorization Requirements for Praluent in South Dakota

Prior authorization is the single biggest logistical hurdle for South Dakota patients seeking Praluent. Most commercial plans operating in South Dakota, including Wellmark Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Medica, require step-therapy documentation before approving a PCSK9 inhibitor [12].

The standard PA documentation package typically includes:

1. A fasting lipid panel dated within the past 90 days showing LDL-C above the plan's threshold.
2. Documentation of at least one maximally tolerated statin trial, usually requiring both a high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) and a reason the dose could not be increased further.
3. Documentation of ezetimibe 10 mg trial in many plans, particularly for commercial ASCVD indications.
4. The ICD-10 code and clinical narrative linking the indication to the FDA-approved label.
5. Prescriber signature and NPI number.

ODYSSEY OUTCOMES data support the clinical case: the number needed to treat to prevent one major cardiovascular event over the 2.8-year median follow-up was 63 patients [3]. Presenting this datum in the PA letter can strengthen the clinical justification narrative.

HealthRX Prior Authorization Readiness Checklist for South Dakota Praluent Applications

| Document | Typical Payer Requirement | Notes | |---|---|---| | Fasting lipid panel | Within 90 days | LDL-C threshold varies by plan (often 70 or 100 mg/dL) | | Statin trial record | At least 1 high-intensity statin | Dose and duration must be specified | | Ezetimibe trial | Required by many SD commercial plans | 10 mg daily for at least 90 days | | Genetic testing or DLCN score | HeFH indications only | DLCN score 6 or higher may substitute | | ICD-10 code | E78.01 (HeFH) or I25.10 (ASCVD) | Confirm with plan's formulary criteria | | Prescriber NPI | Always required | Telehealth prescribers must be SD-licensed |

Appeals succeed in a meaningful proportion of initial denials. A 2021 analysis in Circulation found that PCSK9 inhibitor PA appeals were successful in approximately 55% of cases when supported by detailed clinical documentation and a letter from a cardiologist [13].

South Dakota Medicaid and Coverage Gaps

South Dakota Medicaid does not cover Praluent as of 2025. This is a concrete gap for low-income South Dakota residents who qualify for Medicaid but have high cardiovascular risk. South Dakota's Medicaid expansion under the Affordable Care Act took effect July 1, 2023, adding approximately 45,000 newly eligible adults [14], but alirocumab remains excluded from the SD Medicaid preferred drug list.

Patients without commercial insurance or with Medicaid coverage have two main options:

Regeneron/Sanofi patient assistance program. The Praluent Savings Card reduces out-of-pocket cost for eligible commercially insured patients to as low as $0 per month. For uninsured patients below 600% of the federal poverty level, the manufacturer's patient assistance program may provide alirocumab at no cost [6].

Clinical trials. Patients at Sanford Health and Monument Health research centers may be eligible for lipid-lowering trials that provide study medication at no charge. ClinicalTrials.gov lists active lipid management studies recruiting in South Dakota [15].

Medicare Part D plans vary in their Praluent coverage. Some plans place alirocumab on Tier 4 or Tier 5 with significant cost sharing, while others require separate PA. Patients should run a formulary check at Medicare.gov using their specific plan ID before assuming coverage.

Pharmacy Logistics: How Long Until You Receive Praluent in South Dakota

The timeline from prescription submission to first injection typically runs 10 to 21 days for South Dakota patients, broken down as follows.

PA processing by the insurer takes 3 to 15 business days depending on the plan. Urgent or expedited PA review, which is available when the prescriber certifies that the standard timeline would seriously jeopardize the patient's health, must be completed within 72 hours under federal managed care rules [16].

Once PA is approved, the specialty pharmacy ships Praluent overnight in a temperature-controlled package. Alirocumab requires refrigeration at 2°C to 8°C (36°F to 46°F) but may be stored at room temperature (below 25°C) for up to 30 days [1]. Delivery to remote South Dakota addresses, including reservation communities such as the Cheyenne River Sioux Tribe reservation or the Pine Ridge area, is feasible via FedEx and UPS overnight shipping, though patients should confirm a reliable delivery address.

The MyPraluent hub can coordinate delivery to a local pharmacy pickup point if home delivery is not practical [6].

503A Compounding of Alirocumab in South Dakota

Licensed 503A compounding pharmacies in South Dakota may prepare alirocumab for patients with a valid individual prescription. 503A pharmacies operate under state board of pharmacy oversight and compound drugs on a patient-specific, prescription-by-prescription basis, as distinct from 503B outsourcing facilities that produce sterile products in bulk [17].

Compounded alirocumab is not FDA-approved and carries different quality assurance standards than the brand-name product. Regeneron's manufacturing process includes proprietary formulation elements that a compounding pharmacy cannot fully replicate. The FDA has not issued any shortage designation for alirocumab that would create a formal compounding pathway, so compounded versions exist outside standard formulary coverage [18].

The practical case for compounded alirocumab in South Dakota is narrow: it may serve patients who cannot access brand-name Praluent due to insurance exclusions and who do not qualify for manufacturer assistance. Any patient considering this route should ask the compounding pharmacy for its USP 797 sterile compounding compliance documentation and confirm the pharmacist's license is active with the South Dakota State Board of Pharmacy [19].

Who Can Prescribe Praluent in South Dakota

South Dakota allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe alirocumab. Each has the legal authority to initiate and manage PCSK9 inhibitor therapy under South Dakota Code Title 36, which governs health professional licensing [20].

NPs in South Dakota practice under a collaborative agreement with a physician for the first three years of practice, after which they may practice independently. PAs require a supervising physician agreement. Both NPs and PAs can initiate Praluent prescriptions provided their collaborative or supervising physician is on file. Many cardiology and internal medicine practices in Sioux Falls, Rapid City, and Aberdeen employ NPs and PAs who routinely manage lipid-lowering therapy.

Cardiologists and clinical lipidologists are the most experienced prescribers and are best positioned to write a compelling PA letter. If a primary care provider initiates the prescription, a referral note from a cardiologist or lipidologist strengthens the PA submission significantly, particularly for HeFH indications where the clinical picture may be less familiar to payer medical directors.

Transferring an Existing Praluent Prescription to South Dakota

Patients relocating to South Dakota with an existing Praluent prescription from another state can transfer the prescription to a South Dakota-licensed prescriber. The transfer process involves three steps.

First, the patient requests that their current prescriber send records, including the most recent lipid panel, the PA approval letter, and the medication history, to a South Dakota provider. Second, the South Dakota provider reviews the records and either co-signs the existing prescription (if the specialty pharmacy permits) or writes a new prescription and submits a new PA if required. Third, the specialty pharmacy updates the shipping address.

Most specialty pharmacy PA approvals are plan-specific, not state-specific, so a patient with commercial insurance through a national carrier like Aetna, Cigna, or United Healthcare can typically keep the same PA approval after moving to South Dakota as long as the plan does not change. State Medicaid is not transferable.

A new in-state prescriber visit (including telehealth) is recommended within 90 days of relocating to South Dakota to ensure continuity and to order updated labs if the previous panel is older than 90 days [4].

Dosing and Administration for South Dakota Patients

Alirocumab is available in two doses: 75 mg/mL and 150 mg/mL, each in a 1-mL single-dose prefilled pen or syringe. The standard starting dose for most patients is 75 mg subcutaneously every two weeks. If the LDL-C response at 4 to 8 weeks is insufficient, the dose may be up-titrated to 150 mg every two weeks [1].

A once-monthly 300 mg dose (two simultaneous 150 mg injections) is an FDA-approved alternative for patients who prefer monthly administration. This can simplify adherence for patients in remote South Dakota communities where routine medication management is challenging.

Patients inject alirocumab themselves at home, rotating between the abdomen, thigh, or upper arm. Training is typically provided by the specialty pharmacy via a pharmacist phone consultation or video tutorial. The MyPraluent program also offers nurse support for injection training [6].

In ODYSSEY LONG TERM (N=2,341 to 78 weeks), alirocumab 150 mg every two weeks produced a mean LDL-C reduction of 61.0% from baseline versus placebo (P<0.001) [21]. Patients with baseline LDL-C above 100 mg/dL saw the largest absolute reductions. The drug was well tolerated, with injection-site reactions occurring in 7.2% of alirocumab-treated patients versus 5.1% on placebo.